Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08BPS
|
|||
| Drug Name |
JCAR017
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 1/2 | [1], [2] | |
| leukaemia [ICD-11: 2A60-2B33; ICD-9: 208.9] | Phase 1/2 | [3] | ||
| B-cell non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 1 | [4] | ||
| Follicular lymphoma [ICD-11: 2A80; ICD-9: 202] | Phase 1 | [1], [5] | ||
| Mantle cell lymphoma [ICD-11: 2A85.5; ICD-10: C83.1] | Phase 1 | [1], [5] | ||
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 1 | [1], [5] | ||
| Primary mediastinal B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3] | Phase 1 | [5] | ||
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Clinical trial | [1] | ||
| Company |
Juno Therapeutics, Inc.
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-lymphocyte surface antigen B4 (CD19) | Target Info | CAR-T-Cell-Therapy | [1], [2], [5] |
| KEGG Pathway | PI3K-Akt signaling pathway | |||
| Hematopoietic cell lineage | ||||
| B cell receptor signaling pathway | ||||
| Epstein-Barr virus infection | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | IL-7 Signaling Pathway | |||
| Panther Pathway | B cell activation | |||
| Pathway Interaction Database | BCR signaling pathway | |||
| Reactome | PIP3 activates AKT signaling | |||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
| Constitutive Signaling by Aberrant PI3K in Cancer | ||||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
| WikiPathways | Human Complement System | |||
| Signaling by the B Cell Receptor (BCR) | ||||
| PIP3 activates AKT signaling | ||||
| B Cell Receptor Signaling Pathway | ||||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | |||
| REF 2 | ClinicalTrials.gov (NCT03331198) Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041076) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | ClinicalTrials.gov (NCT02631044) Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.